CPHI Worldwide Announces Members of its 2015 Expert Panel

CPHI Worldwide, organised by UBM EMEA, announces its Expert Panel for CPHI Worldwide 2015 ahead of the eagerly anticipated annual report (3rd edition) — to be released September and October 2015, in three parts. The report presents a holistic overview of pharmaceuticals with key industry leaders providing expertise across the entire pharma supply chain.

This year, the CPHI annual report will see the return of seven industry thought leaders from 2014, along with three new valuable additions; Vivek Sharma, Alan Sheppard and Kurt Nielson of Piramal, IMS Health and Sandoz respectively.

Vivek Sharma, CEO of Piramal Critical Care & Pharma Solutions replaces his colleague Vijay Shah to provide insights from one of the most innovative companies within the sector. Alan Sheppard, Principal of Global Generics & Thought Leadership at IMS Health will be giving an overview of the huge global growth of generics and examining its impact over the next 5–10 years.

There is a significant shift occurring in the dynamics of drugs consumption and expenditure globally, which is having consequences not only for generic manufacturers but also in the development of new drugs. For example, Kurt Nielsen, Vice President of US Development, Portfolio and Launch Management at Sandoz, will share his invaluable insights on how to optimise development programmes and new bring new drugs to market faster.

“CPHI’s expert panel provides leading expertise on all aspects of pharmaceuticals from different global perspectives. The 2014 report examined major issues and developments across the industry including regulatory challenges from a globalised industry to cost savings through manufacturing process, QbD and PAT.

This year’s annual report will continue to expand the scope of reputable insights across the pharma industry, looking to analyse future trends, regulatory risks and supply chain issues. The new additions to the 2015 panel increase our breadth of expertise across the pharma industry even further, and keep our annual report analysis at the forefront of the pharma news agenda.” Chris Kilbee, Group Director Pharma at UBM EMEA.